ClinicalTrials.gg

Program

zamtocabtagene autoleucel

Also written as “MB-CART2019.1”, “zamtocabtagene autoleucel (MB-CART2019.1)” and “MB-CART2019.1 Dose level 1”.

Its studies are mostly in Lymphoma, B-Cell · Melanoma · Lymphoma, Large B-Cell, Diffuse · Lupus Nephritis · Multiple Sclerosis, led by Miltenyi Biomedicine.

Furthest: phase 2, since Feb 25, 20218 company-led studies, 7 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Miltenyi Biomedicine87 open or runningphase 2since Feb 25, 2021Feb 25, 2019Dec 31, 2026phase 2 · NCT04792489

Also a collaborator on its studies: PPD, Part of Thermo Fisher Scientific and ICON.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 25, 2019First study: phase 1 study in Lymphoma, B-CellFirst studyNCT03870945 · 12 enrolled · Germany
  2. Feb 25, 2021Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT04792489 · 315 planned · United States, Canada
  3. Jun 11, 2024No phase study in MelanomaNCT06508775 · 40 planned · Germany
  4. Jul 2, 2024Phase 2 study in Lymphoma, B-CellNCT06508931 · 31 planned · France, Germany, Italy and more
  5. Nov 26, 2024Phase 1 study in Lupus NephritisNCT06708845 · 48 planned · United States
  6. Jul 28, 2025Phase 2 study in Multiple SclerosisNCT07178431 · 26 planned · Germany
  7. Nov 20, 2025Phase 2 study in Dendritic Cell Sarcoma, InterdigitatingNCT07288879 · 31 planned · Japan
  8. Apr 28, 2026Phase 2 study in Lymphoma, Mantle-CellNCT07569965 · 52 planned

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT04792489
  2. Jan 31, 2027Primary completion: phase 2 study in Dendritic Cell Sarcoma, InterdigitatingNCT07288879
  3. Jan 2028Primary completion: phase 1 study in Lupus NephritisNCT06708845
  4. Sep 2029Primary completion: phase 2 study in Lymphoma, Mantle-CellNCT07569965

TargetBeta

“A preparation of autologous CD4/CD8 enriched T-lymphocytes engineered to express pLTG1497, a tandem chimeric antigen receptor (CAR) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, ”NCIt, by rule

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07569965Lymphoma, Mantle-Cell2Not yet recruitingSep 202952
NCT07288879Dendritic Cell Sarcoma, Interdigitating · Japan2RecruitingJan 31, 202731
NCT07178431Multiple Sclerosis · Germany2RecruitingAug 16, 203026
NCT06708845Lupus Nephritis · United States1RecruitingJan 202848
NCT06508931Lymphoma, B-Cell · France, Germany, Italy and more2RecruitingDec 31, 202931
NCT06508775Melanoma · Germany–RecruitingDec 31, 204040
NCT04792489Lymphoma, Large B-Cell, Diffuse · United States, Canada2RecruitingDec 31, 2026315
NCT03870945Lymphoma, B-Cell · Germany1CompletedDec 17, 202012

How it is read

Names in the registry

  • “MB-CART2019.1”, 3 entries
  • “zamtocabtagene autoleucel (MB-CART2019.1)”, 3 entries
  • “zamtocabtagene autoleucel”, 1 entry
  • “MB-CART2019.1 Dose level 1”, 1 entry
  • “MB-CART2019.1 Dose level 2”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.